Blend Therapeutics Lands $16,000,000 Series B Funding Round

  • Feed Type
  • Date
    12/18/2012
  • Company Name
    Blend Therapeutics
  • Mailing Address
    134 Coolidge Avenue Watertown, MA 02472
  • Company Description
    Blend is pioneering controlled combination medicines that overcome the limitations of conventional combination therapy through their unprecedented ability to hit distinct disease pathways with multiple drugs in concert—at the desired sites, at the most effective concentrations, and for the right durations—to drive optimal effects from each drug on the disease process.
  • Website
    http://www.blendtx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $16,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will be used to expand Blend’s product and business development teams and to advance the company’s lead programs through studies to enable filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA).
  • M&A Terms
  • Venture Investor
    NanoDimension
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    Flagship Ventures

By posting a comment, you agree to our terms and conditions.